Evidence map›Paper›PMID 25232429›Full record

ArticleInternational journal of clinical and experimental medicine2014

Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Can Dolapcioglu, Aysun Koc-Yesiltoprak, Emel Ahishali, Aziz Kural, Hatice Dolapcioglu, Aliye Soylu, Resat Dabak

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Can DolapciogluDepartment of Gastroenterology, Dr. Lutfi Kirdar Kartal Research and Training Hospital Kartal, Istanbul, Turkey.
Aysun Koc-YesiltoprakDepartment of Family Medicine, Dr. Lutfi Kirdar Kartal Research and Training Hospital Kartal, Istanbul, Turkey.
Emel AhishaliDepartment of Gastroenterology, Dr. Lutfi Kirdar Kartal Research and Training Hospital Kartal, Istanbul, Turkey.
Aziz KuralDepartment of Gastroenterology, Dr. Lutfi Kirdar Kartal Research and Training Hospital Kartal, Istanbul, Turkey.
Hatice DolapciogluDepartment of Pathology, Fatih Sultan Mehmet Research and Training Hospital Istanbul, Turkey.
Aliye SoyluDepartment of Gastroenterology, Dr. Sadi Konuk Bakirkoy Research and Training Hospital Bakirkoy, Istanbul, Turkey.
Resat DabakDepartment of Family Medicine, Dr. Lutfi Kirdar Kartal Research and Training Hospital Kartal, Istanbul, Turkey.
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRFatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sequential treatment scheme has been developed to overcome resistance problem in H. pylori eradication and favorable results have been obtained. This study compared the results of standard triple therapy with a sequential schema consisting of pantoprazole, amoxicillin, clarithromycin, and metronidazole in a high anti-microbial resistance setting. This retrospective study included subjects that underwent standard or sequential eradication treatment after a diagnosis of biopsy-documented H. pylori infection. Patients either received pantoprazole 40 mg bid, amoxicillin 1000 mg bid and clarithromycin 500 mg bid (PAC) for 10 days, or pantoprazole 40 mg bid and amoxicillin 1000 mg bid (PA) for the first 5 days of the treatment period and were then given pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid (PCM) in the remaining 5 days. Eradication was tested using urea breath test. The two treatment groups did not differ with regard to H. pylori eradication rate for both ITT population (63.9% versus 71.4% for standard and sequential therapy respectively, P = 0.278) and per protocol population (65.9% versus 74.1% for standard and sequential therapy respectively, P = 0.248). Although a sequential treatment appears to represent a plausible alternative, our findings suggest that alternative schedules may be required in certain populations to achieve higher success rates.

Indexed as

eradicationH. pylorisequential therapystandard therapy

Identifiers

PMID25232429
PMCPMC4161589
OpenAlexW267017515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.